Here’s what you should know:
1. Research by Philadelphia-based Perelman School of Medicine HIV/Viral Hepatitis Coinfection Scientific Working Group Co-Director Vincent Lo Re, MD, stated that cured patients, even those that are HCV antibody-positive, are at risk for reinfection.
2. Researchers haven’t established set reinfection rates among patients treated with direct-acting antiviral agents because studies are still ongoing.
3. Early findings show patients engaging in high-risk behaviors, like those who inject drugs, face heightened reinfection risks.
4. Reinfected patients need to undergo the same evaluation process a first-time patient would to determine appropriate course of treatment.
More articles on gastroenterology:
Nevada Supreme Court overturns 2nd-degree murder conviction against gastroenterologist linked to Las Vegas hepatitis C outbreak — 4 insights
Olympus to pay $6.6M in duodenoscope-related damages — 6 key takeaways
Renewed interest in gastroparesis research brings cure into focus — 4 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
